세계의 인공 폐 시장 : 부문별 예측(2025-2030년)

The Artificial Lung Market was valued at USD 7.02 billion in 2023, expected to reach USD 7.63 billion in 2024, and is projected to grow at a CAGR of 8.76%, to USD 12.65 billion by 2030.

The artificial lung market encompasses devices and technologies that replicate or support the gas exchange functions of biological lungs, primarily to manage respiratory failures or diseases. With a growing prevalence of chronic respiratory diseases worldwide, the demand for artificial lung systems is becoming increasingly vital. Applications span from temporary respiratory support in intensive care units to alternatives in transplant scenarios, where lung availability is limited. Automotive, medical research, and healthcare sectors serve as end-use domains, with an increasing interest from biotechnology firms due to advancements in materials and biocompatible technologies. A significant growth driver is the rise in chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS) cases, as well as the global aging population, which boosts market potential. Innovations in biomaterials leading to improved device lifespan, alongside the development of portable and implantable artificial lungs, offer lucrative opportunities. However, challenges like high manufacturing costs, stringent regulatory requirements, and potential biocompatibility issues may impede market growth. To capitalize on opportunities, companies should focus on enhancing device efficiency and ergonomics through research into nanotechnology and biocompatible polymers. There is also potential in exploring hybrid systems that combine mechanical support with biological tissue engineering. The nature of the market is both competitive and ripe for innovation, dominated by key players investing in R&D to outpace challenges and regulatory hurdles. As an analyst, I recommend investing in collaborations with medical research institutions and exploring public-private partnerships to foster innovation and facilitate regulatory compliance. Expanding into emerging markets, which may have less stringent regulations, could offer easier entry points and further market penetration. Enhanced focus on patient-centric approaches, such as developing personalized artificial lung solutions, could also bolster adoption and improve patient outcomes, driving market expansion.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Artificial Lung Market

The Artificial Lung Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of respiratory diseases and lung transplantation driving demand for artificial lungs
  • Technological advancements in artificial lung design and functionality driving industry growth
  • Growing investment and funding in research and development of artificial lung systems
  • Rising geriatric population coupled with higher incidences of chronic lung conditions enhancing market demand
• Market Restraints
  • Limited availability of skilled professionals and expertise needed for the operation and maintenance of artificial lung devices
  • Concerns regarding biocompatibility and long-term durability of artificial lung materials affecting adoption rates
• Market Opportunities
  • Development of ai-driven artificial lungs to optimize respiratory support systems
  • Regenerative medicine approaches for creating long-lasting and durable artificial lungs
  • Integration of internet of things (iot) with artificial lungs for real-time monitoring and maintenance
• Market Challenges
  • Technological limitations and reliability concerns stalling the widespread acceptance of artificial lungs in healthcare settings
  • Ethical considerations and public perception issues influencing the R&D and deployment of artificial lungs

Porter's Five Forces: A Strategic Tool for Navigating the Artificial Lung Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Artificial Lung Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Artificial Lung Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Artificial Lung Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Artificial Lung Market

A detailed market share analysis in the Artificial Lung Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Artificial Lung Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Artificial Lung Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Artificial Lung Market

A strategic analysis of the Artificial Lung Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Artificial Lung Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ALung Technologies, Inc., B. Braun Melsungen AG, Baxter International Inc., Breethe, Inc., CardiacAssist, Inc., Cleveland Clinic, Dragerwerk AG & Co. KGaA, Fresenius Medical Care AG & Co. KGaA, Getinge AB, Hemovent GmbH, Maquet Holding B.V. & Co. KG, McGowan Institute for Regenerative Medicine, Medtronic plc, Novalung GmbH, Organ Care System (OCS), Respiratory Assist, Terumo Corporation, Xenios AG, and Xenios USA, Inc.

Market Segmentation & Coverage

This research report categorizes the Artificial Lung Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product Type, market is studied across Extracorporeal Membrane Oxygenation (ECMO), Intrapulmonary Gas Exchange, and Paracorporeal Artificial Lungs.
• Based on Technology, market is studied across Oxygenator Technology, Pump Technology, and Sensors and Monitors.
• Based on Patient Age Group, market is studied across Adult, Geriatric, Neonates, and Pediatric.
• Based on Component, market is studied across Cannulas, Controllers, Membrane Oxygenators, and Pumps.
• Based on Application, market is studied across Acute Respiratory Distress Syndrome (ARDS), Cardiopulmonary Bypass, and Chronic Obstructive Pulmonary Disease (COPD).
• Based on End-User, market is studied across Ambulatory Surgical Centers, Clinics, and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of respiratory diseases and lung transplantation driving demand for artificial lungs
    • 5.1.1.2. Technological advancements in artificial lung design and functionality driving industry growth
    • 5.1.1.3. Growing investment and funding in research and development of artificial lung systems
    • 5.1.1.4. Rising geriatric population coupled with higher incidences of chronic lung conditions enhancing market demand
  • 5.1.2. Restraints
    • 5.1.2.1. Limited availability of skilled professionals and expertise needed for the operation and maintenance of artificial lung devices
    • 5.1.2.2. Concerns regarding biocompatibility and long-term durability of artificial lung materials affecting adoption rates
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of ai-driven artificial lungs to optimize respiratory support systems
    • 5.1.3.2. Regenerative medicine approaches for creating long-lasting and durable artificial lungs
    • 5.1.3.3. Integration of internet of things (iot) with artificial lungs for real-time monitoring and maintenance
  • 5.1.4. Challenges
    • 5.1.4.1. Technological limitations and reliability concerns stalling the widespread acceptance of artificial lungs in healthcare settings
    • 5.1.4.2. Ethical considerations and public perception issues influencing the R&D and deployment of artificial lungs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Artificial Lung Market, by Product Type

• 6.1. Introduction
• 6.2. Extracorporeal Membrane Oxygenation (ECMO)
• 6.3. Intrapulmonary Gas Exchange
• 6.4. Paracorporeal Artificial Lungs

7. Artificial Lung Market, by Technology

• 7.1. Introduction
• 7.2. Oxygenator Technology
• 7.3. Pump Technology
• 7.4. Sensors and Monitors

8. Artificial Lung Market, by Patient Age Group

• 8.1. Introduction
• 8.2. Adult
• 8.3. Geriatric
• 8.4. Neonates
• 8.5. Pediatric

9. Artificial Lung Market, by Component

• 9.1. Introduction
• 9.2. Cannulas
• 9.3. Controllers
• 9.4. Membrane Oxygenators
• 9.5. Pumps

10. Artificial Lung Market, by Application

• 10.1. Introduction
• 10.2. Acute Respiratory Distress Syndrome (ARDS)
• 10.3. Cardiopulmonary Bypass
• 10.4. Chronic Obstructive Pulmonary Disease (COPD)

11. Artificial Lung Market, by End-User

• 11.1. Introduction
• 11.2. Ambulatory Surgical Centers
• 11.3. Clinics
• 11.4. Hospitals

12. Americas Artificial Lung Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Artificial Lung Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Artificial Lung Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2023
• 15.2. FPNV Positioning Matrix, 2023
• 15.3. Competitive Scenario Analysis
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. ALung Technologies, Inc.
• 3. B. Braun Melsungen AG
• 4. Baxter International Inc.
• 5. Breethe, Inc.
• 6. CardiacAssist, Inc.
• 7. Cleveland Clinic
• 8. Dragerwerk AG & Co. KGaA
• 9. Fresenius Medical Care AG & Co. KGaA
• 10. Getinge AB
• 11. Hemovent GmbH
• 12. Maquet Holding B.V. & Co. KG
• 13. McGowan Institute for Regenerative Medicine
• 14. Medtronic plc
• 15. Novalung GmbH
• 16. Organ Care System (OCS)
• 17. Respiratory Assist
• 18. Terumo Corporation
• 19. Xenios AG
• 20. Xenios USA, Inc